Open AccessIn vivo Pharmacokinetic and Anticancer Studies of HH-N25, a Selective Inhibitor of Topoisomerase I, and Hormonal Signaling for Treating Breast Cancer
Author(s) -
Bashir Lawal,
Yi Chun Kuo,
Maryam Rachmawati Sumitra,
Alexander T.H. Wu,
HsuShan Huang
Publication year - 2021
Publication title -
journal of inflammation research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.656
H-Index - 33
ISSN - 1178-7031
DOI - 10.2147/jir.s329401
Subject(s) - in vivo , pharmacokinetics , pharmacology , breast cancer , volume of distribution , cancer , chemistry , topoisomerase , medicine , in vitro , biology , biochemistry , microbiology and biotechnology
Breast cancer is the most frequently diagnosed cancer globally, and the leading cause of cancer-associated mortality among women. The efficacy of most clinical chemotherapies is often limited by poor pharmacokinetics and the development of drug resistance by tumors. In a continuing effort to explore small molecules as alternative therapies, we herein evaluated the therapeutic potential of HH-N25, a novel nitrogen-substituted anthra[1,2-c][1,2,5]thiadiazole-6,11-dione derivative.